Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?
BrightSpring Health Services is gaining acute infusion share with 20%+ volume growth, targeting 12-15 new states in a $20 billion market.
Zacks
More News
Zacks Industry Outlook Highlights DaVita, LifeStance Health, Option Care Health, and Aveanna Healthcare
Outpatient and home healthcare stocks gain from aging, digital care and AI, with LifeStance, Option Care, Aveanna and DaVita in focus.
Zacks
4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds
An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.
Zacks
OPCH or CHE: Which Is the Better Value Stock Right Now?
OPCH vs. CHE: Which Stock Is the Better Value Option?
Zacks
Are Investors Undervaluing Option Care Health (OPCH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
Option Care Health (OPCH) Q2 2026 Earnings Call Transcript
OPCH vs. PNTG: Which Stock Is the Better Value Option?
OPCH vs. PNTG: Which Stock Is the Better Value Option?
Zacks
Is Option Care Health (OPCH) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
BTSG Raises 2026 Guidance as Specialty and Home Health Drive Growth
BrightSpring beat second-quarter estimates and raised its 2026 outlook as specialty, infusion and home health growth lifted margins and EBITDA.